HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Belizna C., Pregnolato F., Abad S., Alijotas-Reig J., Amital H., Amoura Z., ...Daha Fazla

AUTOIMMUNITY REVIEWS, cilt.17, sa.12, ss.1153-1168, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 17 Sayı: 12
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.autrev.2018.05.012
  • Dergi Adı: AUTOIMMUNITY REVIEWS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1153-1168
  • Hacettepe Üniversitesi Adresli: Evet

Özet

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3].